Results 131 to 140 of about 467,609 (357)
Aurora kinases play critical roles in regulating several processes pivotal for mitosis. Radotinib, which is approved in South Korea as a second-line treatment for chronic myeloid leukemia, inhibits the tyrosine kinase BCR-ABL and platelet-derived growth ...
Sook-Kyoung Heo +10 more
doaj +1 more source
Histone 3 lysine18 lactylation (H3K18la) drives heterogeneous nuclear ribonucleoprotein C (HNRNPC) overexpression, activating autophagy to mediate gemcitabine resistance by stabilizing TNF receptor‐associated factor 6 (TRAF6) mRNA. Concurrently, HNRNPC stabilizes aldehyde dehydrogenase 1 family member A3 (ALDH1A3) mRNA, which enhances glycolysis and ...
Xi‐Tai Huang +9 more
wiley +1 more source
This study shows that monocytes in multiple myeloma display an excessive interferon response, leading to transcriptional reprogramming and altered differentiation. Using single‐cell sequencing, coculture experiments, and patient samples before and after therapy, the authors demonstrate that induction treatment reduces this interferon response ...
Jian Cui +18 more
wiley +1 more source
Stability and Bifurcation of the Immune Model of Chronic Myeloid Leukemia with Time Delay
In order to investigate the effects of the differentiation delay in chronic myeloid leukemia stem cells on the dynamic behaviors among chronic myeloid leukemia stem cells, chronic myeloid leukemia mature cells and effector T cells, a delayed immune ...
WANG Jingnan, SUN Yue
doaj +1 more source
Optimized Treatment Schedules for Chronic Myeloid Leukemia
Over the past decade, several targeted therapies (e.g. imatinib, dasatinib, nilotinib) have been developed to treat Chronic Myeloid Leukemia (CML). Despite an initial response to therapy, drug resistance remains a problem for some CML patients.
Dingli, David +4 more
core +3 more sources
CDK4/6 inhibition promotes CD8+ T cell expansion through tumor‐macrophage crosstalk by activating HIF‐1α and enhancing MIF‐CD44/CD74 signaling. This reprograms TAMs to boost MHC‐I antigen presentation, and CDK4/6 inhibitor‐trained M1 TAM supernatant therapy synergizes with low‐dose PD‐1 blockade to restore antitumor immunity.
Lin He +17 more
wiley +1 more source
Diagnosis and management of chronic myeloid leukemia [PDF]
Hagop M. Kantarjian +5 more
openalex +1 more source
Therapy of Acute Myeloid Leukemia
The Eastern Cooperative Oncology Group (ECOG) has recently reviewed the outcome for more than 1,400 patients with previously untreated AML entered on five successive clinical trials.5,6 Each trial included daunorubicin and cytarabine for induction.
openaire +2 more sources
Acute myeloid leukemia (AML) remains a therapeutic challenge due to its heterogeneity and limited targets. Here, multi‐omics analyses are utilized, and it is revealed that AML cells, particularly the FLT3‐ITD+ subtype, undergo chaperone‐mediated ER stress, inducing surface translocation of ER chaperones.
Yimin Zhou +13 more
wiley +1 more source
Margaret R, O'Donnell +19 more
openaire +2 more sources

